These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21421724)

  • 1. Optimization of hapten-peptide labeling for pretargeted immunoPET of bispecific antibody using generator-produced 68Ga.
    Karacay H; Sharkey RM; McBride WJ; Rossi EA; Chang CH; Goldenberg DM
    J Nucl Med; 2011 Apr; 52(4):555-9. PubMed ID: 21421724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates.
    Griffiths GL; Chang CH; McBride WJ; Rossi EA; Sheerin A; Tejada GR; Karacay H; Sharkey RM; Horak ID; Hansen HJ; Goldenberg DM
    J Nucl Med; 2004 Jan; 45(1):30-9. PubMed ID: 14734668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts.
    van Rij CM; Frielink C; Goldenberg DM; Sharkey RM; Franssen GM; Lütje S; McBride WJ; Oyen WJ; Boerman OC
    Mol Imaging Biol; 2015 Feb; 17(1):94-101. PubMed ID: 25060065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.
    Bodet-Milin C; Faivre-Chauvet A; Carlier T; Rauscher A; Bourgeois M; Cerato E; Rohmer V; Couturier O; Drui D; Goldenberg DM; Sharkey RM; Barbet J; Kraeber-Bodere F
    J Nucl Med; 2016 Oct; 57(10):1505-1511. PubMed ID: 27230928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
    McBride WJ; Zanzonico P; Sharkey RM; Norén C; Karacay H; Rossi EA; Losman MJ; Brard PY; Chang CH; Larson SM; Goldenberg DM
    J Nucl Med; 2006 Oct; 47(10):1678-88. PubMed ID: 17015905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts.
    Schoffelen R; Sharkey RM; Goldenberg DM; Franssen G; McBride WJ; Rossi EA; Chang CH; Laverman P; Disselhorst JA; Eek A; van der Graaf WT; Oyen WJ; Boerman OC
    Mol Cancer Ther; 2010 Apr; 9(4):1019-27. PubMed ID: 20354120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody.
    van Rij CM; Lütje S; Frielink C; Sharkey RM; Goldenberg DM; Franssen GM; McBride WJ; Rossi EA; Oyen WJ; Boerman OC
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1377-83. PubMed ID: 23674207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells.
    Rossi EA; Chang CH; Losman MJ; Sharkey RM; Karacay H; McBride W; Cardillo TM; Hansen HJ; Qu Z; Horak ID; Goldenberg DM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7122s-7129s. PubMed ID: 16203811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
    Cardillo TM; Karacay H; Goldenberg DM; Yeldell D; Chang CH; Modrak DE; Sharkey RM; Gold DV
    Clin Cancer Res; 2004 May; 10(10):3552-61. PubMed ID: 15161715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
    van Schaijk FG; Broekema M; Oosterwijk E; van Eerd JE; McBride BJ; Goldenberg DM; Corstens FH; Boerman OC
    J Nucl Med; 2005 Jun; 46(6):1016-22. PubMed ID: 15937314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multistep tumor targeting in nude mice using bispecific antibodies and a gallium chelate suitable for immunoscintigraphy with positron emission tomography.
    Schuhmacher J; Klivényi G; Matys R; Stadler M; Regiert T; Hauser H; Doll J; Maier-Borst W; Zöller M
    Cancer Res; 1995 Jan; 55(1):115-23. PubMed ID: 7805020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy.
    Janevik-Ivanovska E; Gautherot E; Hillairet de Boisferon M; Cohen M; Milhaud G; Tartar A; Rostene W; Barbet J; Gruaz-Guyon A
    Bioconjug Chem; 1997; 8(4):526-33. PubMed ID: 9258451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
    Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
    J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
    Gautherot E; Rouvier E; Daniel L; Loucif E; Bouhou J; Manetti C; Martin M; Le Doussal JM; Barbet J
    J Nucl Med; 2000 Mar; 41(3):480-7. PubMed ID: 10716323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
    Gold DV; Goldenberg DM; Karacay H; Rossi EA; Chang CH; Cardillo TM; McBride WJ; Sharkey RM
    Cancer Res; 2008 Jun; 68(12):4819-26. PubMed ID: 18559529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new Tri-Fab bispecific antibody for pretargeting Trop-2-expressing epithelial cancers.
    Sharkey RM; van Rij CM; Karacay H; Rossi EA; Frielink C; Regino C; Cardillo TM; McBride WJ; Chang CH; Boerman OC; Goldenberg DM
    J Nucl Med; 2012 Oct; 53(10):1625-32. PubMed ID: 22952342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
    van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
    Kraeber-Bodéré F; Faivre-Chauvet A; Ferrer L; Vuillez JP; Brard PY; Rousseau C; Resche I; Devillers A; Laffont S; Bardiès M; Chang K; Sharkey RM; Goldenberg DM; Chatal JF; Barbet J
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3973S-81S. PubMed ID: 14506196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET.
    Schuhmacher J; Klivényi G; Kaul S; Henze M; Matys R; Hauser H; Clorius J
    Nucl Med Biol; 2001 Oct; 28(7):821-8. PubMed ID: 11578904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.